CARsgen's CAR-T Product Satri-cel Included in China's Commercial Health Insurance Innovative Drug List

Résumé détaillé

SHANGHAI, Nov. 14, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces…

SHANGHAI, Nov. 14, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that satricabtagene autoleucel ("satri-cel", product code: CT041), an autologous CAR T-cell therapy product targeting Claudin18.2, has been included in the Commercial Health Insurance Innovative Drug List (2026) (the "CHIIDL") issued by the National Healthcare Security Administration ("NHSA") and the Ministry of Human Resources and Social Security ("MOHRSS"), for the treatment of patients with Claudin18.2-positive, HER2-negative advanced gastric/ gastroesophageal junction adenocarcinoma (G/GEJA) who have failed at…

The CHIIDL primarily covers innovative drugs that go beyond the "basic coverage" mandate of the national basic medical insurance scheme and therefore cannot yet be included in the basic reimbursement list, but which are highly innovative, of significant clinical value, deliver substantial patient benefit, and are well suited to insurance coverage. It provides a payment basis for China's multi-tiered healthcare security system, including commercial health insurance and mutual medical aid.

Taking this inclusion as an opportunity, CARsgen will, on the premise of doing its utmost to ensure product quality and a stable supply, actively support the design and implementation of commercial insurance products and accelerate market access at healthcare institutions and standardized clinical use, so as to bring this first-in-class cell therapy product to more patients as soon as possible.

Dr. Zonghai Li, Founder, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen, stated, "Satri-cel was approved in China this June and has been included in the national CHIIDL within the same year. This is recognition at the national level of the clinical value and the innovation of the world's first CAR T-cell therapy for solid tumors.

Début de l'article, extrait de PR Newswire. Pour lire la suite, ouvrez l'article chez le média.